# Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

> **NCT05860465** · PHASE2,PHASE3 · RECRUITING · sponsor: **Shanghai Pharmaceuticals Holding Co., Ltd** · enrollment: 254 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Breast Cancer

## Interventions

- **DRUG:** SPH4336 Tablets
- **DRUG:** SPH4336 Tablets Placebo

## Key facts

- **NCT ID:** NCT05860465
- **Lead sponsor:** Shanghai Pharmaceuticals Holding Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-08
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-30
- **Target enrollment:** 254 (ESTIMATED)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05860465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05860465, "Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT05860465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*